ArticleImmunotherapy2012
Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity.
Article in Immunotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- The Role of Plasmacytoid Dendritic Cells in Cancers.Frontiers in immunology · 2021Review
- IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.Frontiers in oncology · 2021Article
- Partial Depletion of Regulatory T Cells Enhances Host Inflammatory Response Against Acute Pseudomonas aeruginosa Infection After Sepsis.Inflammation · 2018Article
- Review
- Impact of T cell selection methods in the success of clinical adoptive immunotherapy.Cellular and molecular life sciences : CMLS · 2014Article
- Review
- Cell transfer therapy for cancer: past, present, and future.Journal of immunology research · 2014Review
- Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.Molecular cancer · 2013Article
- Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluation of: Rech AJ, Mick R, Martin S et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patents. Sci. Transl. Med. 4(134), 134ra62 (2012). Tregs are involved in the maintenance of immunological self-tolerance. Recent studies have revealed that Tregs suppress antitumor immunity and that they are major obstacles for cancer immunotherapy. Various approaches have been carried out to cancel immunological suppression by Tregs in clinical settings; however, side effects such as autoimmunity occurred and expected antitumor effects were not achieved. In a recent study, Rech et al. evaluated daclizumab, a US FDA-approved humanized anti-CD25 antibody, for regulation of Treg cells in a peptide vaccination trial of breast cancer patients. Daclizumab caused long-lasting depletion of CD25(+) Tregs, reprogramming of CD25(+) Tregs, and enhancement of antipeptide immune response. Of note, major autoimmune responses were not observed in daclizumab-treated patients. This study provides a possible safe and promising approach to regulate Tregs in cancer vaccine therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.